Silence Therapeutics plc (SLN)

Name: Silence Therapeutics plc (SLN) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Also trades as SLNCF. Every security a company lists rests on one set of financial statements, so these figures cover the whole company.

Build a valuation ↗↓ Download CSV

CIK 0001479615 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing

For the year ended 2025-12-31, Silence Therapeutics plc reported revenue of $559.0K. Revenue fell 98.7% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $615.0K.

Key ratios (year ended 2025-12-31)

61.5%

Gross margin

n/m

Operating margin

n/m

Net margin

-142.2%

Return on year-end equity

-98.7%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-19

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue	$615.0K	$559.0K	$43.26M	$31.64M	$21.66M
Cost of Revenue	$87.0K	$215.0K	$11.81M	$12.87M	$13.46M
Gross Profit	$528.0K	$344.0K	$31.45M	$18.78M	$8.19M
R&D Expense	$47.56M	$67.75M	$67.88M	$56.94M	$43.55M
Operating Income	-$68.31M	-$91.08M	-$63.32M	-$64.38M	-$61.04M
Net Income	-$59.95M	-$88.61M	-$45.31M	-$54.23M	-$50.33M
EPS (Diluted)	n/a	-$0.63	-$0.33	-$0.49	-$0.52
Total Assets	$106.41M	$131.44M	$202.63M	$119.45M	n/a
Total Liabilities	$67.94M	$69.14M	$68.61M	$97.45M	n/a
Shareholders' Equity	$38.47M	$62.30M	$134.02M	$21.99M	$27.22M
Cash & Equivalents	$72.05M	$11.28M	$121.33M	$68.79M	n/a
Operating Cash Flow	-$42.26M	-$62.27M	-$67.64M	-$49.46M	-$57.04M
Capital Expenditures	$3.0K	$55.0K	$211.0K	$56.0K	$173.0K
Free Cash Flow	-$42.27M	-$62.33M	-$67.85M	-$49.52M	-$57.22M
Shares Outstanding	141.74M	141.70M	141.67M	118.85M	107.81M
Weighted Average Diluted Shares	n/a	141.69M	138.75M	111.28M	96.58M
EPS (Basic)	n/a	-$0.63	-$0.33	-$0.49	-$0.52

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView